Separate terms with OR to return results that match either term.
 
Clear All
700 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status (Ascending)
J2425 Palifermin Kepivance 50 mcg Ancillary Therapy Epithelial Growth Factor Keratinocyte Growth Factor/rHuKGF No 2004 Jan. 1, 2006 In Use
J2469 Palonosetron Aloxi 25 mcg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 2003 Jan. 1, 2005 In Use
J2562 Plerixafor Mozobil 1 mg Ancillary Therapy Immunostimulant Stem Cell Mobilizer No 2008 Jan. 1, 2010 In Use
J2783 Rasburicase Elitek, Fasturtec 0.5 mg Ancillary Therapy Metabolic Agent Enzyme No 2002 Jan. 1, 2004 In Use
J8670 Rolapitant Varubi 1 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2015 Jan. 1, 2017 In Use
J2820 Sargramostim Leukine 50 mcg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 1991 Jan. 1, 1998 In Use
NA Uridine Triacetate Xuriden 2 g Ancillary Therapy Chemoprotective Antidote Yes 2015 In Use
NA Uridine Triacetate Vistogard 10 g Ancillary Therapy Chemoprotective Antidote Yes 2015 In Use
J3489 Zoledronic acid Zometa (4 mg/5 ml) 1 mg Ancillary Therapy Bisphosphonate No 2001 Jan. 1, 2014 In Use
NA Estrogens, Conjugated Cenestin, Duavee, Enjuvia, Premarin, Premphase, Prempro Cenestin®, Duavee® (combination), Enjuvia®, Premarin®, Premarin® Intravenous, Premphase® (combination), Prempro® (combination) multiple Hormonal Therapy Estrogen Yes 1998 In Use
J9057 Copanlisib Aliqopa 1mg Chemotherapy Enzyme Inhibitor PI3K No 2017 In Use
Q5111 Pegfilgrastim-cbqv Udenyca 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2019 Jan. 1, 2019 In Use
Q5113 Trastuzumab-pkrb Herzuma 10mg Immunotherapy Monoclonal Antibody HER2 No 2018 July 1, 2019 In Use
Q5114 Trastuzumab-dkst Ogivri 10mg Immunotherapy Monoclonal Antibody HER2 No 2017 July 1, 2019 In Use
Q5115 Rituximab-abbs Truxima 10mg Immunotherapy Monoclonal Antibody CD20 No 2018 July 1, 2019 In Use
J9036 Bendamustine HCL Belrapzo 1mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2018 July 1, 2019 In Use
J9030 Bacillus calmette-guerin BCG Vaccine, Tice BCG 1mg Immunotherapy Biological Response Modifier Live Vaccine No 1990 July 1, 2019 In Use
J9356 Trastuzumab and Hyaluronidase-oysk Herceptin hylecta 10mg Immunotherapy Monoclonal Antibody HER2 No 2019 July 1, 2019 In Use
J9313 Moxetumomab-pasudotox-tdfk Lumoxiti 0.01mg Immunotherapy Drug Antibody Conjugate CD22 No 2018 Oct. 1, 2019 In Use
J9269 Tagraxofusp-erzs Elzonris 10mcg Immunotherapy Recombinant Fusion Protein IL3/CD123 No 2018 Oct. 1, 2019 In Use
J9113 Cemiplimab-rwlc Libtayo 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2018 Oct. 1, 2019 In Use
J9204 Mogamulizumab-kpkc Poteligeo 1mg Immunotherapy Monoclonal Antibody CCR4 No 2018 Oct. 1, 2019 In Use
J9118 Calaspargase pegol-mknl Asparlas 10 units Chemotherapy Miscellaneous Agent Enzyme No 2018 Oct. 1, 2019 In Use
Q5117 Trastuzumab-anns Kanjinti 10mg Immunotherapy Monoclonal Antibody HER2 No 2019 Oct. 1, 2019 In Use
Q5118 Bevacizumab-bvzr Zirabev 10mg Immunotherapy Monoclonal Antibody VEGFR No 2019 Oct. 1, 2019 In Use

Found 700 results in 2 milliseconds — Export these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.